NLS Pharmaceutics enters option agreement with Aexon Labs for dual orexin receptor agonist platform

Dec. 5, 2023

NLS Pharmaceutics Ltd. has entered into an exclusive worldwide option agreement with Aexon Labs Inc.

BioWorld Science Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2026.

Detecting the invisible: minimal residual disease at AACR 2026

BioWorld Science

Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

Illustration of human face that looks abstract and digital

AACR 2026: The age of agentic AI in oncology

BioWorld Science

New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...

Chengdu Mfs Pharma synthesizes new compounds for pain

BioWorld Science

Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...